Platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-snate chronic renal failure (CRF), as well as in hemodialysis (HD) glycero-3-phosphocholine) is a potent phospholipid meand chronic ambulatory peritoneal dialysis (CAPD) patients.
Methods. We studied 74 patients undergoing maintenance diator in inflammatory and allergic reactions. PAF is HD, 44 patients undergoing CAPD, 56 patients with mild/ considered to be significantly involved in several physiomoderate CRF, and 98 healthy subjects whose lipid profile, as pathological conditions and may have pivotal roles in well as plasma and high-density lipoprotein (HDL)-associated several syndromes or diseases, including renal diseases PAF-AH activity, was determined. Moreover, the effect of [1] [2] [3] . It has been shown that PAF is produced in the Lp(a) plasma levels on the distribution of PAF-AH among plasma lipoproteins, as well as the specific activity and kinetic healthy kidney by endothelial, mesangial, and renal medproperties of PAF-AH on two different Lp(a) isoforms, was ullary cells [4] [5] [6] . Studies in experimental animals and measured in each studied group.
in humans indicate that PAF may be an important media-
Results. The plasma PAF-AH activity in all studied groups tor of renal damage, suggesting that its production and was significantly higher than in controls, and the increase was action in the kidney may be dysregulated in disease states more profound in CAPD patients. The HDL-associated PAF-AH activity, expressed per milliliter of plasma, was similar [3] . PAF has a short half-life time in plasma and is deamong all studied groups; however, when it was expressed as graded to the inactive metabolite lyso-PAF by PAFeither per milligrams of HDL cholesterol or per milligrams of acetylhydrolase (PAF-AH; EC 3.1.1.47), which catalyzes plasma apolipoprotein (apo) AI, the PAF-AH activity was the hydrolysis of the esterified acetate at the sn-2 position significantly higher in all patient groups compared with controls. All patient groups had significantly elevated plasma Lp(a) [7] . PAF-AH also hydrolyzes phospholipids containing levels, which altered the distribution of PAF-AH among the oxidatively fragmented residues at the sn-2 position [8] .
plasma lipoproteins compared with that observed in subjects Such phospholipids are formed during the oxidative with very low plasma Lp(a) levels (Ͻ8 mg/dl). Additionally, modification of low-density lipoprotein (LDL) and are in each studied group, the specific activity as well as the apparthought to play key roles in the inflammatory reactions ent K m and V max values of the 19K4 apo(a) isoform were significantly higher (P Ͻ 0.01) compared with the values of the 23K4 nal function [14] , whereas it has recently been reported shown in Table 1 . The HD schedule was for four hours three times per week using cuprophane or hemophane that it was unaltered in patients with renal failure underhollow fiber dialyzers and acetate (N ϭ 6) or bicarbonate going hemodialysis (HD) [15, 16] .
(N ϭ 68) dialysate containing 2 g/liter glucose. CAPD Lipoprotein(a) [Lp(a)] is an LDL-like particle distinpatients performed four exchanges per day with twoguished from LDL by the presence of apolipoprotein(a) liter solutions of 1.86 or 3.86% glucose, depending on [apo(a)], a high molecular mass glycoprotein that shows the individual need for ultrafiltration. All patients had remarkable size polymorphism, which is attached to apo been free of peritonitis at least three months preceding B-100 through disulfide linkage [17, 18] . Apo(a) is highly blood sampling. The method of replacement therapy was homologous to the plasma protease zymogen plasminothe initial treatment in most patients of both groups. gen, and thus, it has been suggested that Lp(a) may
Patients with a different method of replacement at the promote thrombogenesis by inhibiting fibrinolysis [19, onset of dialysis had to be on the present therapy for at 20]. High plasma Lp(a) levels are considered to be an least six months before their inclusion in the study. The independent risk factor for atherosclerosis in both Cauadequacy of the dialytic treatment was evaluated by the casian and Oriental populations [21, 22] . In recent years, Kt/V ratio, which ranged from 1.2 to 1.4 for HD patients several reports have shown that serum Lp(a) concentraand from 1.9 to 2.0 (weekly) in CAPD patients. Patients tions are increased in patients with end-stage renal diswith mild/moderate CRF did not have significant proease (ESRD) and that the Lp(a) serum concentration is teinuria (urine protein Ͻ1 g/24 hr). The renal diagnosis an independent factor contributing to the risk of atherofor all patients was chronic pyelonephritis in 28 patients, sclerotic disease, which is the major cause of morbidity chronic glomerulonephritis in 88 patients, hypertensive and mortality in both HD and chronic ambulatory peritonephropathy in 6 patients, and polycystic kidney disease neal dialysis (CAPD) patients [23] [24] [25] [26] [27] .
in 9 patients; the origin of CRF was unknown in the As it has been shown previously [28, 29] , Lp(a) is remaining patients. Patients and controls with a known enriched in PAF-AH, which is mainly associated with the family history of primary hyperlipidemia, excessive alcoapo B rather than the apo(a) moiety of the lipoprotein hol consumption, diabetes mellitus, obesity (body mass particle. We have also suggested that the apo(a) moiety index Ͼ30 kg/m 2 ), liver disease, systemic illnesses, or of Lp(a) affects the kinetic properties of the enzyme, as other metabolic or endocrine disorders were excluded the specific activity and apparent K m and V max values from the study. Patients received no other medication are significantly decreased as the apo(a) isoform size except polyvitamins, calcitriol, phosphate binders, and increased [28] . Furthermore, using a gradient ultraceniron. In hypertensive patients, angiotensin-converting trifugation method, we have shown that in healthy subenzyme inhibitors, calcium channel blockers, or both jects, Lp(a) alters the enzyme distribution between LDL were also given. In some CRF patients, frusemide 20 to and HDL in a concentration-dependent fashion [28] .
60 mg/day per os was also administered. Thirty-one HD To the best of our knowledge, there is a paucity of patients and 22 CAPD patients were on erythropoietin data concerning PAF-AH activity in total plasma and in treatment. Lp(a) of uremic patients undergoing dialysis. We underBlood samples were taken in patients and controls took this study in order to evaluate plasma PAF-AH after a 14-hour overnight fast for the determination of activity in patients with mild/moderate chronic renal failserum lipid parameters, serum albumin, prealbumin, creure (CRF), as well as in HD and in CAPD patients and atinine, and PTH levels, as well as plasma PAF-AH its association with lipid abnormalities, and to clarify, in activity. In HD patients, fasting blood was obtained bethis clinical context, Lp(a)-associated PAF-AH activity, fore dialysis, whereas in 30 HD patients, blood was also as well as the Lp(a) isoform-dependent effect on the taken immediately after dialysis for the determination enzyme-specific activity and kinetic constants.
of PAF-AH activity. In CAPD patients, fasting venous blood was drawn without interruption of CAPD. In patients with CRF, proteinuria was determined on 24-hour METHODS urine samples, and creatinine clearance was also calcuStudy population lated. In dialysis patients, the residual renal function Seventy-four patients undergoing maintenance HD, estimated by the average of the residual creatinine and 44 patients undergoing CAPD, 56 patients with mild/ urea clearances was almost negligible (Ͻ5.0 ml/min). moderate CRF (serum creatinine 1.8 to 8 mg/dl, and Analytical methods creatinine clearance 10 to 60 ml/min), and 98 subjects selected from individuals receiving medical check-up at Serum cholesterol and triglycerides were determined our hospital who were free from any illness by history, by enzymatic colorimetric assay using an RA-1000 anaphysical examination, and routine laboratory data (conlyzer (Technicon Instruments, Tarrytown, NY, USA), whereas HDL cholesterol was determined enzymatically trol group) were studied. Population characteristics are Values represent either the mean Ϯ sd, or the a median (range). Abbreviations are: HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF, undialyzed patients with mild/moderate chronic renal failure; PTH, parathyroid hormone; SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant differences among the studied groups.
b By one-way analysis of variance c By Kruskal-Wallis test in the supernatant after precipitation of other lipoproLipoprotein(a) isolation teins with dextran sulfate-magnesium. LDL cholesterol Three subjects from each patient group and controls was calculated using the Friedewald formula [30] if fastpresenting with a single apo(a) isoform band of either ing triglyceride levels were less than 400 mg/dl. Serum 19 K4 or 23 K4 and with plasma Lp(a) levels higher than apo AI and apo B were measured by immunonephe-20 mg/dl were selected in order to isolate Lp(a) and study lometry with the aid of a Beckman array analyzer (Beckthe kinetic properties of PAF-AH. Lp(a) was isolated man Instruments, Palo Alto, CA, USA). Lp(a) was meaby density gradient ultracentrifugation followed by gel sured using a monoclonal anti-Lp(a) antibody technique filtration chromatography on Sepharose 6B column, as described previously [28] . To avoid any oxidation, Lp(a) by the enzyme immunoassay Macra Lp(a) (Terumo was prepared in the presence of 0.3 mm ethylenediamineMedical Corporation Diagnostic Division, Elkton, MD, tetraacetic acid (EDTA). Furthermore, Lp(a) prepara-USA). Serum and urine creatinine were measured by tions were stored in the presence of EDTA at 4ЊC under the Jaffé method and serum albumin by the bromocresol nitrogen and were used within two weeks. The absence green method. Serum prealbumin was measured by imof oxidation in our Lp(a) preparations was confirmed munonephelometry, and serum parathyroid hormone by agarose gel electrophoresis (Hydragel LipoϩLp(a) (PTH) levels were measured by radioimmunometric kit; Sebia), as well as by the thiobarbituric acid reactive assay [24, 25] .
substances (TBARS) assay [33] . The Lp(a) preparations were essentially free of any other lipoprotein or albumin Apolipoprotein(a) phenotyping as evaluated by both nondenaturing 2 to 16% gradient Apolipoprotein(a) isoform size was determined by polyacrylamide gel electrophoresis (PAGE) [34] and by agarose gel electrophoresis in 1.5% sodium dodecyl sulgradient 5 to 19% SDS-PAGE, followed by immunoblotfate (SDS)-agarose gels followed by immunoblotting, ting using sheep polyclonal anti-apo(a) and anti-apo B-100 according to the method of Kamboh, Ferrell, and Kottke antibodies and revealed by chemiluminescence. The lipid [31] , as modified by Doucet et al [32] . Isoform size was content of Lp(a), that is, cholesterol, triglycerides, and expressed as number of kringle 4 (K4) repeats by using phospholipids, was analyzed by enzymatic methods using a standard with five different apo(a) isoforms (35, 27, 23 , BioMerieux kits (Marcy l'Etoile, France) and the protein 19, and 14 K4) obtained from Immuno AG (Innsbruck, content by the bicinchoninic acid method. Lipoprotein Austria).
mass was calculated as the sum of all lipid and protein components. Lp(a) was stored under nitrogen and used Fractionation of plasma lipoproteins within two weeks after preparation. Plasma lipoproteins were fractionated by density graPlatelet-activating factor-acetylhydrolase assay dient ultracentrifugation in a Beckman L7-65 ultracentrifuge at 40,000 r.p.m., 15ЊC for 24 hours, using a type SW Platelet-activating factor-AH activity was measured 41 rotor as described previously [28] . After ultracentrifuby the trichloroacetic acid (TCA) precipitation procegation 28 fractions of 400 l were collected by successive dure [12] . A [ 3 H]-PAF solution with a concentration of aspiration from the meniscus downward. All fractions 1 mm (specific activity 2000 cpm/nmol) containing PAF were analyzed for their cholesterol and Lp(a) content (hexadecyl; Bachem, Zurich, Switzerland), and 1-O-hexadecyl-2-[ mmol; DuPont-New England Nuclear, Boston, MA, patients exhibited significantly higher serum total cholesterol, LDL cholesterol, and apo B levels compared with USA), 1 mmol/liter, prepared as previously described [12] , was used as a substrate for PAF-AH. The enzyme the other patient groups or controls. Moreover, the atherogenic risk ratio of total cholesterol/HDL cholesterol activity in plasma or HDL was measured as already mentioned [35] . PAF-AH activity was also determined in 25 was significantly higher in this patient group compared with HD or CRF patients. All patient groups had inl of each gradient fraction and on Lp(a) using 10 g of Lp(a) protein [28] . The reaction was performed for creased serum Lp(a) concentrations when compared with controls (Table 2) . Although CAPD patients exhib-10 minutes at 37ЊC by adding 10 l of [ 3 H]-PAF (100 mol/liter final concentration). PAF-AH activity was exited higher serum Lp(a) levels than HD and CRF patients, the differences were not statistically significant. pressed as nmol PAF degraded per minute per ml of plasma or per mg HDL cholesterol or per mg apo AI.
In none of the patients' groups were serum Lp(a) concentrations correlated with the other lipid parameters or Lp(a)-associated PAF-AH activity was expressed per mg of Lp(a) protein or mg of Lp(a) mass. The kinetic age or with serum creatinine, albumin, prealbumin, or PTH levels. Additionally, no correlation between serum properties of Lp(a)-associated PAF-AH were evaluated in each isoform using 2.5 to 100 l [ 3 H]-PAF final concenLp(a) concentrations and dialysis duration was present in either dialysis group. tration as described [28] . The apparent K m and V max values of the enzyme were calculated using the LineweaverPlasma and HDL-associated PAF-AH activity Bü rk representation of the data.
As shown in Figure 1 , the plasma PAF-AH activity Statistical analysis in all patient groups was higher than controls (P Ͻ 0.005 for CRF and HD before dialysis and P Ͻ 0.001 for CAPD Values are expressed as mean Ϯ sd, except for age and Lp(a), which are expressed in terms of median and patients). Additionally, the enzyme activity in CAPD patients was significantly higher compared with either range. A comparison of continuous variables was performed by unpaired two-tailed t-test, as well as by one-HD or CRF patients (P Ͻ 0.001 for both comparisons), whereas no difference was observed between HD and way analysis of variance with multiple Scheffe-type comparisons. Because of the highly skewed distribution of CRF patients. The enzyme activity also studied in 30 HD patients immediately after dialysis revealed no dif-PTH and Lp(a), the nonparametric Mann-Whitney U-test and the Kruskal-Wallis test were applied to discriminate ference compared with that observed before dialysis (68.8 Ϯ 13.6 vs. 64.4 Ϯ 15.6 nmol/ml/min, respectively, for differences of these parameters between groups. The distribution of plasma PAF-AH activity was tested for P ϭ NS). No significant differences in the plasma PAF-AH activity were observed in HD patients using cupronormality using the Kolmogorov Smirnov test. Because the PAF-AH activity values did not significantly differ from phane compared with those using hemophane hollow fiber dialyzers (data not shown). The PAF-AH activity normal distribution in all studied groups, one-way analysis of variance (with Fisher's least significant difference in controls, HD, and CRF patients was correlated with total cholesterol, LDL cholesterol, and apo B levels (Tamethod for multiple comparisons) was used to compare PAF-AH activity among groups. The same procedure was ble 3). Additionally, in all patient groups, the enzyme activity was correlated with the triglyceride levels (Table used to assess the differences in specific activity and kinetic constants of PAF-AH associated with two different 3). Interestingly, in CAPD patients, no correlation was observed between the plasma PAF-AH activity and total apo(a) isoforms. Correlations between PAF-AH activity and covariates were estimated using Pearson's correlacholesterol, LDL cholesterol, or apo B levels, whereas an inverse correlation with HDL cholesterol and apo AI tion coefficients. Spearman's rank correlation coefficients were used to evaluate the degree of association between levels was noticed (Table 3) . PAF-AH activity was not significantly correlated with Lp(a) levels in all studied Lp(a) and other values. Pearson's 2 test was used to assess the difference in prevalence between the studied groups, although the correlation coefficient values in all patient groups were higher compared with controls (Tagroups. Significance levels were set at 0.05 in all cases. ble 3). No correlation was found between the enzyme activity and the mean blood pressure values in all studied RESULTS groups (data not shown). Finally, the plasma enzyme Patients' lipid profile activity in CRF patients was not correlated with plasma creatinine levels or with creatinine clearance values (TaAs shown in Table 2 , all patient groups had significantly increased serum triglyceride and decreased HDL ble 3). The HDL-associated PAF-AH activity, expressed per cholesterol and apo AI levels compared with controls. The atherogenic risk ratio of total cholesterol/HDL chomilliliter of plasma, was similar among all studied groups (6.2 Ϯ 3.2 nmol/ml plasma/min for controls, 6.6 Ϯ 1.6 for lesterol was also significantly higher in all patient groups in comparison with normal subjects. Interestingly, CAPD HD patients, 6.7 Ϯ 1.1 for CAPD, and 6.6 Ϯ 1.4 for CRF group with Lp(a) levels ranging from 31 to 51 mg/dl was fractionated into 28 fractions by density gradient ultracentrifugation. Lp(a) was not detectable in any gradient fraction or it was migrated as a narrow band in fractions 12 to 15 (d ϭ 1.064 to 1.095) in the plasma of subjects with Lp(a) levels Ͻ8 mg/dl. By contrast, in plasma with Lp(a) levels 31 to 51 mg/dl, it was migrated in fractions 9 to 17 (d ϭ 1.050 to 1.100 g/ml) independently of the apo(a) isoform size, as we have previously reported [28] . A representative curve of the lipoprotein profile obtained is shown in Figure 3A . No difference in the PAF-AH activity (expressed as a percentage of the total activity recovered in all gradient fractions) was observed among all studied groups for the same range of Lp(a) concentrations (Fig. 3B) . By contrast, the enzyme activity distributed in fractions 9 to 17 was significantly tein (VLDL) plus the major part of LDL] contained 19.5 Ϯ 3.2% of total enzyme activity in all studied groups and the fractions 18 to 28 (the major part of HDL plus proteins) contained 33.4 Ϯ 5.2%. Finally, in plasma with patients). It is important to note that the HDL-associated Lp(a) levels 31 to 51 mg/dl, the fractions 1 to 8 contained PAF-AH activity when expressed as either per milligram 20.1 Ϯ 5.3% of total enzyme activity in all studied groups, of HDL cholesterol or per milligram of plasma apo AI and the fractions 18 to 28 contained 24.6 Ϯ 4.8%, which was significantly higher in all patient groups compared was significantly lower (P Ͻ 0.04) compared with the with controls (Fig. 2) . Also, similar results for the enzyme same fractions from plasma with Lp(a) levels Ͻ8 mg/dl. activity in plasma or in HDL were obtained when the patients receiving calcitriol, angiotensin-converting en-PAF-AH activity on different Lp(a) isoforms zyme inhibitors, calcium channel blockers, or frusemide Lipoprotein(a) isoforms with 19 K4 repeats or 23 K4 were excluded from the statistical analysis.
repeats were isolated from three subjects of each group Effect of Lp(a) on the distribution of PAF-AH who had plasma Lp(a) levels higher than 20 mg/dl, activity among plasma lipoproteins after whereas the Lp(a) mass as well as the PAF-AH specific gradient ultracentrifugation activity and kinetic constants were determined on each isoform. No oxidation was observed in each Lp(a) prepaPlasma from six subjects of each studied group with Lp(a) levels Ͻ8 mg/dl and from six subjects of each ration, as its electrophoretic mobility in agarose gels was Abbreviations are: PAF-AH, platelet-activating factor acetylhydrolase; HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF, undialyzed patients with mild/moderate chronic renal failure.
a P Ͻ 0.05
not different than that of the Lp(a) band obtained after CRF who received HD [16] . Unlike these results, our study showed that HD patients exhibit significantly plasma electrophoresis of the same subject. Additionally, higher enzyme activity compared with controls. Furtherthe TBARS values were 0.9 Ϯ 0.3 nmol of malondialdemore, PAF-AH activity in patients with mild/moderate hyde equivalents per mg of Lp(a) protein. The Lp(a) CRF was not different from that of HD patients, whereas mass was not different between the two isoforms in all no correlation between serum creatinine levels or creatistudied groups (0.6 Ϯ 0.2 mg/ml plasma). As shown in nine clearance values and plasma PAF-AH activity was Table 4 , the PAF-AH specific activity, as well as the observed in this patient group. Thus, these results proapparent K m and V max values of the 19 K4 apo(a) isoform, vide evidence that the degree of the renal dysfunction in each studied group, was significantly higher compared does not influence the plasma PAF-AH activity and furwith the values of the 23 K4 isoform of the same group ther confirm the observation of other studies indicating (P Ͻ 0.01 for all comparisons). It is also important to that the kidney is not a major source of the plasma note that the specific activity as well as the K m and V max enzyme pool [14, 15] . Our study also shows that the values on either the 19 K4 apo(a) isoform or the 23 plasma PAF-AH activity is significantly higher in CAPD K4 isoform in CAPD patients were significantly higher patients compared with HD or CRF patients, suggesting compared with the values of the same apo(a) isoform in an association between plasma PAF-AH activity and the other patient groups as well as in controls (Table 4) . dialysis procedure. It is well documented that CRF is a clinical state of DISCUSSION impaired immunoreactivity with high susceptibility to In this study, we showed that the plasma PAF-AH infections [36] . Several studies have demonstrated the activity is increased in patients with renal failure with presence of inflammatory mediators in an ongoing acuteor without renal replacement therapy. This elevation in phase reaction in CRF patients not requiring dialysis, as the enzyme activity was more pronounced in patients well as in patients with ESRD undergoing HD or CAPD undergoing CAPD. All patient groups had significantly [37, 38] . In this context, an association between severe higher plasma levels of Lp(a), which alter the distribution renal disease (that is, CRF, primary glomerulonephritis) of PAF-AH among the plasma lipoproteins. The specific and increased PAF production leading to elevated plasma activity and kinetic constants of PAF-AH associated with PAF levels has been reported, whereas PAF may have Lp(a) of two different isoforms with 19 K4 repeats or a prominent role in renal glomerular pathology [14, 15] . 23 K4 repeats were significantly higher in CAPD patients Thus, the increase in plasma PAF-AH activity found in compared with the other patient groups or with controls, this study may represent a protective response to the whereas no difference was observed between controls inflammatory actions of PAF. Alternatively, it has been and HD or CRF patients.
previously shown that the plasma PAF-AH activity is Changes in plasma PAF-AH activity have been reincreased in both clinical and experimental hypertension ported in various diseases [13] , although in most of these [39, 40] . Because PAF is a strong hypotensive agent [41] , studies, the mechanisms underlying the reported alterthe increase in plasma PAF-AH activity may well be part ations in the enzyme activity are not clear yet. Especially of a regulatory counter-response mechanism in arterial in renal failure, only recently was it reported that the blood pressure homeostasis. However, according to our results, the plasma PAF-AH activity was not related to plasma PAF-AH activity is unaltered in patients with type SW 41 rotor at 40,000 r.p.m., 15ЊC for 24 hours, and PAF-AH activity was determined by the TCA precipitation method, by using 25 l of gradient fractions as the source of the enzyme. Data are expressed as means Ϯ sd.
blood pressure values in all studied groups. Additionally, the more profound increase in the plasma PAF-AH activity in CAPD patients can not be explained by this assump- [37] . Thus, it is unlikely that the increased PAF-AH tion, as there were no significant differences in the mean activity in the plasma of these patients is due to enhanced blood pressure values among the patient groups.
secretion from macrophages. It has been reported that Indeed, in this study, we do not provide experimental PAF stimulates the synthesis and secretion of PAF-AH data for the mechanisms responsible for the increased from the liver [45] . Consequently, because of the in-PAF-AH activity in the plasma of our patients. However, creased PAF production in renal failure, it is more likely it is known that the major sources of the plasma enzyme that the liver may be the main source of the increased are monocyte-derived macrophages and liver cells [42, PAF-AH in plasma of these patients. Additionally, in 43]. The secretion of PAF-AH from macrophages is suppatients with renal failure and especially in CAPD papressed in the presence of various cytokines, such as tients, a stimulation of hepatic synthesis of proteins as tumor necrosis factor-␣ and interleukin-1␤ [44] , which are increased in the plasma of patients with renal failure well as of lipoproteins is observed [46] . This pronounced hepatic secretion of proteins may also explain the sigpatient groups compared with controls. Like previous studies, a strong correlation between plasma PAF-AH nificantly higher enzyme activity in CAPD patients compared with CRF or with HD patients. Because it has been activity and LDL cholesterol levels was found in all groups except for CAPD patients. It has been suggested hypothesized that the secretion of the enzyme occurs independently of the secretion of lipoprotein particles that the correlation observed between these two parameters reflects a process that is probably the rate of LDL and then it associates with them [47], a direct increased synthesis of PAF-AH might be the underlying mechaclearance, which influences both of these variables [51] . This could also explain the positive correlation between nism of the increased enzyme activity in this population.
The HDL-associated enzyme activity expressed per PAF-AH activity and apo B levels revealed in our study.
The absence of such a correlation in CAPD patients is mg of HDL cholesterol or mg of apo AI was significantly higher in the patient groups compared with controls, intriguing and may be related to a more pronounced derangement of lipid metabolism characterizing this dialsuggesting an enrichment of HDL with PAF-AH activity. However, when the enzyme activity was expressed per ml ysis procedure. In fact, the elevated hepatic lipoprotein secretion consequent upon protein losses in the dialysis of plasma, it was similar among all groups, because of the lower HDL cholesterol levels observed in the patient fluid and increased carbohydrate absorption via the peritoneum is of paramount importance for the development groups compared with controls. It has been suggested that the HDL-associated paraoxonase and PAF-AH activities of dyslipidemia in these patients [46] . Thus, an increased LDL synthesis rather than a retarded LDL clearance is work in concert to detoxify the lipid peroxides formed on LDL during oxidation, thus providing HDL with an the main mechanism responsible for the increased LDL levels in CAPD patients [46] , leading to the absence of anti-atherogenic potency [48] . The increased HDL-associated PAF-AH activity found in our patients could correlation between PAF-AH activity (dependent on the rate of LDL removal) and LDL cholesterol levels. counteract the reduced paraoxonase activity observed by some investigators in such patients, which could result Significantly elevated plasma Lp(a) concentrations, a typical feature of uremic dyslipidemia [23] [24] [25] [26] [27] , were obin a decreased HDL antioxidant capacity [16, 49] .
All patient groups exhibited a moderate hypertriglycserved in all patient groups. We have already stated that the distribution of PAF-AH among the LDL and HDL eridemia, which is a characteristic feature of uremic dyslipidemia [50] . Our results show that the PAF-AH activsubfractions in plasma studied by density gradient ultracentrifugation is influenced by the plasma Lp(a) levels ity is positively correlated with plasma triglyceride levels in all patient groups but not in controls. This association in an Lp(a) concentration-dependent fashion [28] . Our results confirm these observations showing that the presbetween PAF-AH and serum triglycerides has already been observed, although the biochemical mechanism(s) ence of Lp(a) in plasma alters the distribution of PAF-AH among the plasma lipoproteins, as the PAF-AH activity for this correlation has not been yet elucidated [51, 52] . Although PAF-AH activity has been found on VLDL in the density region of Lp(a) (fractions 9 to 17) is increased accompanied by a decrease in fractions 18 to 28 [12, 53] , an elevation in plasma VLDL concentration does not increase the plasma PAF-AH activity, an indicain subjects from all studied groups having plasma Lp(a) levels 31 to 51 mg/dl compared with those with Lp(a) tion suggesting that any correlation between plasma PAF-AH activity and triglyceride levels is unlikely to levels Ͻ8 mg/dl. However, the distribution of PAF-AH activity in these gradient fractions was not different reflect a direct causal association between these two parameters [51] . Accordingly, our density gradient ultraamong the studied groups with the same range of plasma Lp(a) levels despite the significant differences in the centrifugation experiments showed no increase in the enzyme activity associated with fractions 1 to 8 in all plasma enzyme activity among these groups. Accord-
